Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Arcellx, Inc. - Common Stock
(NQ:
ACLX
)
65.51
-0.41 (-0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
609,948
Open
64.86
Bid (Size)
61.00 (5)
Ask (Size)
67.20 (1)
Prev. Close
65.92
Today's Range
64.08 - 67.37
52wk Range
30.88 - 75.10
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Via
InvestorPlace
Exposures
Product Safety
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
Via
Investor's Business Daily
Performance
YTD
+16.67%
+16.67%
1 Month
+21.88%
+21.88%
3 Month
+22.33%
+22.33%
6 Month
+19.48%
+19.48%
1 Year
+93.59%
+93.59%
More News
Read More
The Latest Analyst Ratings For Arcellx
June 18, 2024
Via
Benzinga
Expert Ratings For Arcellx
May 31, 2024
Via
Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Via
InvestorPlace
Analyst Expectations For Arcellx's Future
May 14, 2024
Via
Benzinga
Peering Into Arcellx's Recent Short Interest
April 15, 2024
Via
Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
February 29, 2024
Via
Benzinga
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
January 04, 2024
Via
Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 09, 2024
From
Arcellx, Inc.
Via
Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Arcellx Provides First Quarter 2024 Financial Results
May 09, 2024
From
Arcellx, Inc.
Via
Business Wire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
Via
InvestorPlace
Arcellx to Participate in Two Upcoming Investor Conferences
May 07, 2024
From
Arcellx, Inc.
Via
Business Wire
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Arcellx, Inc.
Via
Business Wire
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 20, 2024
From
Arcellx, Inc.
Via
Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Via
Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
Via
InvestorPlace
Decoding Bearish Analog And The Warning Signs You Can't Ignore
February 07, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
January 16, 2024
Via
InvestorPlace
Exposures
Product Safety
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
Via
Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
Via
InvestorPlace
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 12, 2023
Via
Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
December 11, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.